Semaphorin 4D in critically ill patients
The Biomedica soluble SEMAPHORIN 4D Assay Kit (sSEMA4D) was utilized in a recent study assessing the role of sSEMA4D in critically ill and septic patients as a biomarker for prediction and disease severity or survival (1). The results revealed that blood SEMA4D concentrations are increased in patients with liver cirrhosis and are positively correlated with liver function tests. The study suggests that sSEMA4D may be associated with hepatic injury and inflammation and may serve as a potential biomarker in critically ill patients with liver cirrhosis.
Semaphorin 4D in critically ill patients
About Semaphorin 4D
Semaphorin 4D (Sema4D) also known as CD100 is a member of the Sema4D family with established immunregulatory functions (2). Sema 4D exists as a membrane bound and in a soluble form. It is expressed on immune cells and is upregulated upon cellular activation resulting in shedding of its extracellular soluble Sema4D domain. This soluble biologically active form has a molecular weight of 120KD and can be measured in blood samples (3, 4). Due to its regulatory role in the immune system the potential application of Sema4D as a diagnostic marker and as a therapeutic target for the treatment of immunological disorders is currently under investigation (5).
Biomedica soluble SEMAPHORIN 4D (sSEMA4D) ELISA Assay Kit (cat. no. BI-20405)
Features & Benefits
- Only Sema4D ELISA assay that is fully validated
- 10 µl / well sample volume – no sample predilution
- Reference values provided
Links to soluble Semaphorin 4D ELISA – protocol booklet – validation data file
Literature
- Soluble Semaphorin 4D Serum Concentrations Are Elevated in Critically Ill Patients with Liver Cirrhosis and Correlate with Aminotransferases. Abu Jhaisha S, Hohlstein P, Yagmur E, Köller V, Pollmanns MR, Adams JK, Wirtz TH, Brozat JF, Bündgens L, Hamesch K, Weiskirchen R, Tacke F, Trautwein C, Koch A. Diagnostics (Basel). 2024 Feb 8;14(4):370. doi: 10.3390/diagnostics14040370. PMID: 38396409; PMCID: PMC10887520.
- The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis. Lontos K, Adamik J, Tsagianni A, Galson DL, Chirgwin JM, Suvannasankha A. Front Endocrinol (Lausanne). 2018 Jun 19;9:322. doi: 10.3389/fendo.2018.00322. PMID: 29971044; PMCID: PMC6018527.
- Soluble SEMA4D/CD100: A novel immunoregulator in infectious and inflammatory diseases. Maleki KT, Cornillet M, Björkström NK. Clin Immunol. 2016 Feb;163:52-9. doi: 10.1016/j.clim.2015.12.012. Epub 2015 Dec 28. PMID: 26732857.
- A high-sensitivity enzyme immunoassay for the quantification of soluble human semaphorin 4D in plasma. Laber A, Gadermaier E, Wallwitz J, Berg G, Himmler G. Anal Biochem. 2019 Jun 1;574:15-22. doi: 10.1016/j.ab.2019.03.004. Epub 2019 Mar 14. PMID: 30879960.
- The role of Sema4D/CD100 as a therapeutic target for tumor microenvironments and for autoimmune, neuroimmune and bone diseases. Wu M, Li J, Gao Q, Ye F. Expert Opin Ther Targets. 2016 Jul;20(7):885-901. doi: 10.1517/14728222.2016.1139083. Epub 2016 Jan 28. PMID: 26732941.